Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Limbo Land For Sarepta, Duchenne And Rare Diseases

Executive Summary

While investors were hopeful the FDA's delay in issuing its verdict for Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy medicine eteplirsen may mean the agency is not prepared to reject it, the postponement may create more doubt and uncertainty about the path forward in rare disease drug development in general.


Related Content

Data Trumps Anecdotes, Emotion At Sarepta Panel
Sarepta Lashed Again; More Duchenne Market Doubt
Duchenne Market Gets Bleaker With Sarepta Eteplirsen Delay
Snowed-Out Sarepta Panel Likely Delays FDA Verdict
Spotlight On Sarepta Post-BioMarin Duchenne Rejection
AbbVie/United Therapeutics $350m Voucher Deal: Smart Move?


Related Companies